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Skin Cancer Screening Focusing on Melanoma 
Yields More Selective Attendance
Michette J. M. de Rooij, MD; Frans H. J. Rampen, PhD; Leo J. Schouten, MD; H. A. Martino Neumann, PhD
Background: Screening theoretically reduces death and 
morbidity from malignant melanoma. The rationale of 
screening for nonmelanoma skin cancer is more debat­
able, since mortality is very low.
Methods: We organized a screening campaign in South­
ern Limburg, the Netherlands, in 1993. Press releases and 
public announcements referred only to melanoma. The 
results were compared with similar campaigns in Arn­
hem and Eindhoven, the Netherlands, in 1990; these, 
however, addressed skin cancer in general.
Results: There were 4146 people attending the 1993 
screenings, compared with 2463 in 1990. The propor­
tion of screenees with lesions suggestive of melanoma in­
creased from 1.1% in 1990 to 1.7% during the 1993 cam­
paign (P=.04). The proportion of dysplastic nevi rose from 
2.1% to 7.7% (PC.001). Nonmelanoma skin cancers were 
less often encountered (3.7% in 1990 vs 2.6% in 1993; 
P=.009). Actinic keratoses were also less numerous (6.3%
vs 1.5%; PC.001).
Conclusion: Screening concentrating on melanoma in­
creases the rates of lesions suggestive of melanoma and 
dysplastic nevi, whereas the proportions of basal and squa­
mous cell carcinomas and actinic keratoses decrease. These 
findings may have important implications with regard to 
the cost-effectiveness of skin cancer screening efforts.
(Arch Dermatol 1995;131:422-425)
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ROGNOS1S OF m alignant tions of melanomas, dysplastic nevi, and 
melanoma depends strongly other pigmented skin lesions and non- 
on early recognition. Screen- melanoma skin cancers, after a screening 
ing as a means of second- program with media attention focusing on 
ary prevention enhances melanoma only, 
early detection and, theoretically, re­
duces death and morbidity from mela- ----------
noma.1,2 Visual examination of the skin by
dermatologists is an acceptable, reliable, In Arnhem and Eindhoven in 1990, a to-
and inexpensive screening tool. Since tal of 2463 participants had been regis-
1985, voluntary skin cancer and mela- tered. The campaign in Southern Lim-
noma screening clinics have been held in burg in 1993 attracted 4146 participants.
the United States.3’7 Similar clinics were There was no marked difference in the sex
organized in the Netherlands in 1989 (Oss) ratio between the 1990 and 1993 exer-
and in 1990 (Arnhem and Eindhoven).8'10 cises. In Arnhem and Eindhoven, 47% of
The screening exercises in the Nether- the screenees were younger than 50 years, 
lands were pilot studies to investigate the compared with 66% in Southern Lim- 
practical implications of such screen- burg. The shift toward younger partici- 
ings. All screenings in the United States pants was highly significant (PC.001). 
and the Netherlands so far have concen- T ab le  1 summarizes the demographic 
trated on skin cancer in general, includ- profile of the attendees at both earn­
ing both melanoma and nonmelanoma paigns. 
skin cancer.
Mortality from nonmelanoma skin 
cancer is low. In terms of health strategy 
priorities, these skin lesions are insignifi­
cant. One may argue that skin cancer 
screening should be confined to malig­
nant melanoma. We studied the propor-
T ab le  2  shows the most relevant
I I V .  r
' i;.
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MATERIALS AND METHODS
In June 1993, free melanoma detection clinics were 
conducted in Southern Limburg, the Netherlands, un­
der the auspices of the Dutch Academy of Dermatol­
ogy and Venereology and the Comprehensive Can­
cer Centers IKL (Maastricht, the Netherlands) and 
IKO (Nijmegen, the Netherlands). The area encom­
passes approximately 650 000 inhabitants. All der­
matologists in the region participated in the study. 
The screenees were examined at six hospital loca­
tions on a fii'st come, first served basis. The program 
was announced in the regional newspapers, on the 
regional radio and television stations, and by post­
ers in waiting rooms of general practitioners and in 
pharmacies and public libraries. Special emphasis was 
placed on the risk factors and symptoms of early ma­
lignant melanoma and its precursor lesions. No ref­
erence was made to the nonmelanoma skin cancers 
and their risk denominators.
Because of the large turnout, skin examina­
tions were confined to specific lesions the atten­
dants were worried about. Systematic examination 
of the entire skin was performed only on those who 
intentionally opted for a complete skin check and on 
those who showed a special skin mark that was sug­
gestive of dysplastic nevus or melanoma. These fac­
tors were the same ones used in the 1990 programs. 
When more than one clinical diagnosis was consid­
ered, only the single worst diagnosis was recorded. 
No biopsies or therapeutic interventions were per­
formed during the screenings.
The participant received a letter of referral with 
the proposed line of management to his or her fam­
ily physician when a cancerous or precancerous le­
sion was suspected. Persons with borderline lesions 
or minimal extent of precursor states were not re­
ferred so as to avoid undue concern and medical treat­
ment. Four months after the campaign, persons with 
a positive screen result were contacted for follow- 
up. Those who did not respond were approached again 
after 10 months.
The results of the Southern Limburg campaign 
were compared with those of two earlier campaigns 
in Arnhem in June 1990 and in Eindhoven in Octo­
ber 1990. The screenings in Arnhem and Eind­
hoven had been planned and executed in a similar 
way, biit die precampaign public releases had em­
phasized skin cancer in general instead of mela­
noma in particular. To test for differences between 
the two populations, the x 2 statistic was used.
findings related to skin malignant neoplasms. The pro­
portion of screenees with lesions clinically suggestive of 
melanoma was higher in 1993 than during the cam­
paigns in Arnhem and Eindhoven. Together, melanoma 
and lentigo maligna were suspected in 1.7% of the 
screenees in 1993, compared with only in 1.1% in 1990 
(P=.Q4). Lesions suggestive of nonmelanoma skin can­
cer were less numerous in 1993. The proportion of per­
sons with presumptive nonmelanoma skin cancer (basal
Clinics in 1990 and 1993
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Numbers of malignant neoplasms/numbers of attendees; percentages 
and P values relate to numbers of attendees.
and squamous cell carcinoma and Bowen’s disease) de­
creased from 3.7% in 1990 to 2.6% in 1993 (P=.009).
Data pertaining to precursor lesions and benign skin 
conditions are presented in Table 3 . At two of six clin­
ics in the Arnhem region, no presumed diagnoses had 
been recorded, apart from skin malignant neoplasms .The 
total number of attendees with evaluable data for pre­
cursor lesions and benign skin marks in 1990 was 1817. 
The proportion of dysplastic nevi had increased substan­
tially in 1993 as compared with 1990. Also, common and 
congenital nevocytic nevi were more frequently encoun­
tered in 1993. However, the proportion of freckles and 
solar lentigines had slightly decreased. Actinic kerato­
ses were distinctly more numerous in 1990 than in 1993.
clinically benign lesions
derma to fibr o mas
eczema
fections, were less often seen during the last screening, 
all at a statistically significant level.
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Table 3. Presumptive Diagnoses of Precursor 
Lesions and Benign Conditions
No. (%)
'
1990* 1993+ -
(n=1817) (n=4146) P
Nevi ■
Nevocellular 724 (39.9) 2333 (56.3) <.001• 1  'i
Dysplastic 38(2.1) 319 (7.7) <.001
Congenital 52 (2.9) 370 (8.9) <.001
Halo 10 (0.6) 43 (1.0) >.05
Blue 9 (0.5) 24 (0.6) >.05
Lentigines, freckles 120 (6.6) 229 (5.5) >.05
Keratoses ■ *  .  * ' .  • '  .
Actinic 114 (6.3) 63 (1.5) <.001
Seborrheic 600 (33.0) 1118 (27.0) <.001
Dermatofibromas 134 (7.4) 194 (4.7) <.001
Vascular lesions 114(6.3) 124 (3.0) <.001
Fibromas, skin tags 89 (4.9) 168 (4.1 ) >.05
Cysts 62 (3.4) 27 (0.7) <.001
Viral warts 43 (2.4) 39 (0.9) <.001
Eczema, psoriasis, • .  •
<.001fungal infections 182 (10.0) 115(2.8)
* Arnhem and Eindhoven, the Netherlands. 
tSouthern Limburg, the Netherlands.
Table 4. Numbers of Malignant Neoplasms 
Confirmed by Pathologic Examination
No. 1%
*
(n
1
S (n»4146) P
Melanomas 
Lentigo maligna 
Melanoma in situ 
Invasive melanomas 
<1 mm
st1 mm 
Thickness unknown 
Totalt
Nonmelanoma skin cancers 
Basal cell carcinoma 
Squamous cell carcinoma 
Bowen’s disease
Totali
1
0
4
3
1
3
1
5
1
0
6/6 (0.3) 13/13
40
1
4
0
1
45/41(2.1) 44/42(1.0) 001
iM m M i
* Arnhem, the Netherlands. 
t Southern Limburg, the Netherlands.
i Numbers of malignant neoplasms/numbers o f attendees; percentages 
and P values for nonmelanoma skin cancers relate to numbers of 
attendees.
§Mann-Whltney U test, considering lesion thickness.
Follow-up of the persons with presumed skin ma­
lignant neoplasms seen in 1990 was only achieved in the 
region of Arnhem, with 1961 participants; no follow-up 
data were available for the clinic held in Eindhoven, with 
502 screenees. In 1993, follow-up was accomplished at 
all clinics in Southern Limburg. The proportion of mela­
nomas confirmed by pathologic examination was simi­
lar in both groups (0.3%). Six melanomas were diag­
nosed in Arnhem and 13 in Southern Limburg. Most 
melanomas diagnosed in Southern Limburg were early 
lesions: only one patient had a melanoma 1 mm thick or
more. In Arnhem, tumor microstage was documented in 
five of six cases; three of these were 1 mm thick or more. 
This shift to thinner lesions was statistically significant 
(P=.04, Mann-Whitney test). The proportion of screenees 
with nonmelanoma skin cancer confirmed by patho­
logic examination was larger in Arnhem than in South­
ern Limburg (2.1% and 1.0%, respectively; P=.001). 
Table 4  gives an overview of the malignant neoplasms 
confirmed by pathologic examination at follow-up.
The difference in age distribution of both study popu­
lations prompted us to perform a logistic regression analy­
sis, including sex and age in the model. For all nevocel- 
lular lesions (common nevi, congenital nevi, dysplastic 
nevi, and melanoma), the odds ratios were statistically 
significantly increased in the Southern Limburg screen­
ing as compared with the Arnhem screening. The odds 
ratio for melanoma, including lentigo maligna, was 1.84 
(95% confidence interval, 1.16 to 2.92).
C O M M E N T
Screening offers much potential for reducing mortality 
from malignant melanoma. However, many questions 
about proper methods of screening for skin cancer and 
melanoma and its ultim ate value remain unan­
swered.1,211'13 Detection campaigns have definite unwar­
ranted effects in terms of creating anxiety and incurring 
extra health expenditures. Since 1985, the American Acad­
emy of Dermatology has been sponsoring open-access 
screening clinics.3’7 Similar clinics have been organized 
in the Netherlands.8"10 So far, attention has been paid to 
both melanoma and nonmelanoma skin cancer. Non- 
melanoma skin cancer is seldom lethal and does not war­
rant screening. Screening confined to melanoma in­
stead of screening for skin cancer in general may 
considerably increase the yield of positive screens.
This study shows that when special emphasis is 
placed on the risk factors and symptoms of malignant 
melanoma and its precursor lesions in the public an­
nouncements and press releases, the percentages of 
screenees attending with skin lesions clinically sugges­
tive of common moles, congenital nevi, dvsülastic nevi.
melanoma
squamous
carcinoma
also applies to benign skin conditions, eg, eczema, pso­
riasis, dermatofibromas, and seborrheic keratoses.
We also compared the biopsy-proved skin malig­
nant neoplasms between both campaigns. Six melano­
mas were recorded in 1990: one lentigo maligna and five 
invasive melanomas. In the 1993 campaign, 13 melano­
mas were diagnosed: four lentigo maligna lesions, three 
in situ superficial spreading melanomas, five invasive mela­
nomas less than 1 mm thick, and only one thick mela­
noma (2.1 mm). Although the proportion of confirmed 
melanomas in both programs was similar (0.3%), the rela­
tive yield of early lesions was distinctly higher in the 1993 
program (P=.04). The total number of confirmed mela­
nomas might have been higher in Southern Limburg if all 
suspected melanoma cases had been followed up. Fol­
low-up was incomplete for two possible melanomas and 
two cases of lentigo maligna. In Arnhem all presumptive
ARCH DERMATOL/VOL 131, APR 1995
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melanoma diagnoses were followed up. The total of 13 con­
firmed melanomas seems rather low. There were 72 po­
tential melanomas diagnosed, including 17 lentigo malig­
nas, in 69 persons. Sixty-eight tumors were adequately 
followed up. This gives a positive predictive value of only 
19%. This low test performance probably results from the 
inclusion of many pigmented lesions with low clinical sus­
picion among the presumptive melanoma diagnoses.
The yield of histologically confirmed dysplastic nevi 
was 48. In Arnhem only 10 dysplastic nevi were histo- 
pathologically confirmed. Despite the incomplete fol- 
low-up of persons with presumed dysplastic nevi in both 
screening exercises, and the rather subjective interpre­
tation of diagnostic minutiae of dysplastic nevi by indi­
vidual dermatologists and histopathologists, we are con­
fident that the true rate of dysplastic nevi was substantially 
higher in the recent campaign.
The peak occurrence of cutaneous melanoma is at 
40 to 50 years of age. Nonmelanoma skin cancer gener­
ally afflicts the elderly. Our 1990 campaigns exhibited a 
relative excess of elderly persons with peak attendance 
rates between 40 ancl 70 years. The 1993 series showed 
a preponderance of aclult screenees, with peak atten­
dance rates between 20 and 50 years. The shift toward a 
younger cohort is encouraging. In this respect, age is prob­
ably not a confounder. Nevertheless, we executed a mul­
tivariate analysis, which disclosed screening location to 
be an independent risk variable. In Southern Limburg, 
significantly more melanomas were clinically diag­
nosed than in Arnhem.
Attendees of skin cancer and melanoma screening 
programs differ from the general population in their risk 
profile.14 People attending in response to the multime­
dia publicity efforts seem to be at appropriately high risk. 
Screening exercises show a relatively high yield of con­
firmed skin cancers, as compared with the expected har­
vest of prevalent cases from the general population.3,6,7,0 
On the other hand, the proper value of self-examination 
and self-selection as a screening tool has been ques­
tioned.15 To maximize the yield of screening, it is im­
perative to tailor programs to attract those persons at high­
est risk. Our survey demonstrates that precampaign
messages must o n
A most promising finding of our project is the de­
creased proportion of nonmelanoma skin cancers and cer­
tain precancerous states of low or negligible clinical and 
epidemiologic concern: basal and squamous cell carci­
nomas ' actinic keratoses. It is questioni
screening procedures can alter the natural course of non­
melanoma skin cancer in a significant proportion of those 
screened. One of the major drawbacks of the rather ttn-
> o n cancer soscreening
far in the United States and in the Netherlands is the ini­
tiation of insignificant and borderline cases into 
cal circuit. Screening only for melanoma may 
means of increasing the detection rate of an i 
and potentially lethal disease. Selective screening f
may de- 
:r of per-
noma may improve cost-e
crease over
sons with minor or c
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